Trials in Philadelphia, Pennsylvania
Here are the top 10 medical studies for retinitis pigmentosa in Philadelphia, Pennsylvania
Popular Filters
Phase 3 Trials
Antioxidant
N-acetylcysteine for Retinitis Pigmentosa
Recruiting1 awardPhase 3
Philadelphia, Pennsylvania
This trial is testing if N-acetylcysteine (NAC) can help slow down vision loss in people with Retinitis Pigmentosa (RP). RP is a genetic condition that causes gradual vision loss. NAC reduces damage caused by too much oxygen around eye cells, potentially protecting vision. N-acetylcysteine (NAC) has been shown to reduce oxidative damage and increase cone function/survival in studies related to RP.
Quinone Analog
Vatiquinone for Friedreich Ataxia
Recruiting2 awardsPhase 3
Philadelphia, Pennsylvania
This trial is testing the long-term safety and effectiveness of vatiquinone in people with Friedreich ataxia who have already used this medication. The goal is to ensure it remains safe and helpful over an extended period. Idebenone, a predecessor to vatiquinone, has been used in Friedreich's ataxia patients and shown positive effects on cardiac hypertrophy.
Glutamate Modulator
Troriluzole for Spinocerebellar Ataxia
Recruiting1 awardPhase 3
Philadelphia, Pennsylvania
This trial is testing whether a medication called Troriluzole can help people with spinocerebellar ataxia by balancing a brain chemical to prevent damage. Troriluzole is related to riluzole, which has been shown to prolong survival and slow functional deterioration in patients with ALS.
Trials With No Placebo
Behavioral Intervention
Exercise Intensity and Balance Training for Spinocerebellar Ataxia
Recruiting1 award6 criteria
New York, New York
This trial is testing two different online exercise routines for people with spinocerebellar ataxias (SCAs). One routine involves intense cardio workouts before balance exercises, while the other involves light exercises like stretching before balance exercises. The goal is to see which routine better improves balance and motor skills in people with SCAs.
Gene Therapy
Gene Therapy for Cardiomyopathy in Friedreich's Ataxia
Recruiting1 awardPhase 1
New York, New York
This trial is testing a gene therapy to treat Friedreich's ataxia, a disease that affects the heart. The therapy uses a virus to deliver the gene. It will be given intravenously to 10 people to see if it is safe and effective.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.